Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canagliflozin versus sitagliptin for cardiac function in high cardiovascular-risk type 2 diabetes
ChiCTR2100051190Phase 4Recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of canagliflozin and sitagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Nanjing Drum-Tower Hospital. Primary endpoint: Global longitudinal strain rate of left ventricle. Started Oct 2021; status: recruiting.
02
Drugs
canagliflozinsitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2100051190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051190.